NCT06699615Enrolling by invitation
Assessing Perceptions of ML Explanations by Medical Oncologists
Survey of Medical Oncologists to Assess Trustworthiness of Various Approaches to AI Explainability for Prognostic Models
Source: ClinicalTrials.gov · Last updated 6 Apr 2026
Brief summary (registry, in English)
The objective of this proposal is to conduct a vignette-based survey among practicing oncology clinicians who treat non-small cell lung cancer to assess the trustworthiness of explainable predictions from a neurosymbolic AI vs. State-of-the-art post-hoc explanatory algorithms, using simulated patient data.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Nov 2024
- Start date
- 2 Dec 2024
- Primary completion date
- 15 Apr 2028
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Childhood cancers
- NCT number
- NCT06699615
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 2 Dec 2024 to the primary completion date, 15 Apr 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Non-medical oncologists No email address or physical address listed Does not treat lung cancer
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.